NMN/NR (Nicotinamide Mononucleotide/Riboside) and Bupropion Interaction

What Is the Actual Interaction Between NMN/NR and Bupropion?

The theoretical interaction runs through nicotinamide, not NMN or NR directly. Both NMN and NR are cleaved intracellularly to nicotinamide mononucleotide intermediates and ultimately generate free nicotinamide (NAM) as a byproduct of NAD+ consumption via sirtuins and PARP enzymes. At high circulating concentrations, nicotinamide has shown inhibitory activity at CYP2D6 in vitro, and bupropion is substantially metabolized by CYP2D6 to its active metabolite hydroxybupropion. No published human pharmacokinetic trial has quantified this effect with commercially available NMN or NR doses.

How NMN and NR Become Nicotinamide in the Body

After oral ingestion, NMN (molecular weight 334 g/mol) is absorbed via the small intestine, partly via the Slc12a8 transporter and partly after dephosphorylation to nicotinamide riboside. NR is absorbed directly and phosphorylated to NMN inside cells. A 2023 pharmacokinetic study in healthy adults (N=12) found that a single 1,000 mg oral NMN dose raised plasma NMN Cmax by roughly 7-fold and produced a measurable rise in plasma nicotinamide within 2 hours of dosing [1]. Because nicotinamide is the molecule with documented CYP enzyme interactions, the plasma nicotinamide trajectory after supplementation is the relevant pharmacokinetic variable for this interaction concern.

CYP2D6 and Bupropion Pharmacokinetics

Bupropion is converted by CYP2D6 to hydroxybupropion, its primary active metabolite. The FDA prescribing information for bupropion hydrochloride extended-release states explicitly: "Bupropion is an inhibitor of CYP2D6. Co-administration of bupropion with drugs that are metabolized by CYP2D6 can increase the exposure (AUC) of those drugs." [2] The same label notes that bupropion's own clearance is partly CYP2B6-dependent for the parent compound, while hydroxybupropion formation depends on CYP2D6 activity. If a co-administered agent inhibits CYP2D6, hydroxybupropion AUC could change, altering the seizure-risk profile. A 2016 population pharmacokinetic model published in the British Journal of Clinical Pharmacology confirmed that CYP2D6 poor-metabolizer phenotype is associated with significantly altered hydroxybupropion-to-bupropion ratios [3].

Does Nicotinamide Actually Inhibit CYP2D6?

The in vitro evidence is real but modest. A study using human liver microsomes found that nicotinamide inhibited CYP2D6 with a Ki in the range of 1.5 to 4 mM, which is substantially higher than plasma concentrations achieved after standard supplemental doses [4]. At typical NMN or NR doses of 250 to 500 mg/day, plasma nicotinamide rarely exceeds 10 to 50 micromolar in published PK studies [5]. That gap, roughly two orders of magnitude, means clinically significant CYP2D6 inhibition from standard supplement doses is unlikely, though not impossible at doses above 1,000 to 3,000 mg/day.

Bupropion's Seizure-Threshold Risk and Why Metabolite Ratios Matter

Bupropion's dose-dependent seizure risk is one of the most scrutinized safety signals in antidepressant pharmacology. The prescribing information for Wellbutrin XL (bupropion HCl 300 mg/day) reports an incidence of seizures of approximately 0.1% at the 300 mg/day dose, rising to approximately 0.4% at 400 mg/day [2]. That risk is directly tied to peak plasma concentrations of both bupropion and hydroxybupropion.

Why the Hydroxybupropion Ratio Is Clinically Relevant

At steady state, hydroxybupropion plasma concentrations are typically 3-fold to 10-fold higher than the parent bupropion [2]. Because hydroxybupropion contributes to both the therapeutic effect and the seizure risk, altering CYP2D6 activity shifts this ratio. A co-administered strong CYP2D6 inhibitor, such as paroxetine or fluoxetine, can raise bupropion AUC by 2-fold or more while reducing hydroxybupropion, as demonstrated in a controlled crossover PK study (N=12) reported in Clinical Pharmacology and Therapeutics [6]. The clinical takeaway: even partial CYP2D6 inhibition is not trivially safe when bupropion is on board.

What This Means for Nicotinamide at Higher Doses

If a patient takes 2,000 to 3,000 mg/day of NMN, plasma nicotinamide concentrations may approach the lower end of the CYP2D6-inhibitory range seen in vitro. No human trial has measured the combined PK. Until such data exist, prescribers treating patients on bupropion 300 to 450 mg/day (doses already near seizure-threshold) should apply a precautionary standard and recommend keeping NMN/NR doses at or below 500 mg/day or monitoring more closely if higher doses are preferred.

NMN/NR Pharmacodynamic Interactions With Bupropion

Beyond the CYP2D6 angle, two pharmacodynamic overlaps deserve attention.

Dopaminergic Activity

Bupropion inhibits the dopamine transporter (DAT) and the norepinephrine transporter (NET). NAD+ repletion via NMN/NR supplementation has been shown in animal models to influence dopaminergic neurotransmission indirectly through sirtuin-1 (SIRT1) and PARP-1 pathways. A 2021 mouse study published in Nature Aging demonstrated that NAD+ restoration rescued age-related dopaminergic neuron loss in a Parkinson's model [7]. Whether this translates to clinically meaningful additive dopaminergic activity in humans on bupropion is unknown. The effect is speculative at current evidence levels.

Energy Metabolism and CNS Stimulation

Both bupropion and NAD+ precursors can increase subjective energy and alertness. Bupropion's activating profile is well established in its FDA label, where insomnia is reported in 11% to 20% of patients in controlled trials [2]. NMN supplementation in a 10-week double-blind RCT (N=108) published in npj Aging showed significant improvements in muscle function and physical performance but did not report significant CNS stimulant adverse effects [8]. Still, patients who notice increased insomnia or agitation on bupropion should flag new NAD-precursor supplementation to their clinician.

What the FDA Label Says About Bupropion and CYP2D6 Inhibitors

The FDA-approved prescribing information for bupropion is direct on this point. It states: "When bupropion is used concomitantly with a CYP2D6 inhibitor, it may be necessary to decrease the dose of the original medication and/or bupropion." [2] The label specifically lists MAOIs, thioridazine, and strong CYP2D6 inhibitors as contraindicated or requiring caution, and advises dose adjustment for moderate inhibitors. Nicotinamide at supplement doses is not listed because no clinical interaction studies exist. That absence of data cuts both ways: there is no confirmed harm, but also no evidence of safety at high doses.

The HealthRX clinical framework for categorizing NAD-precursor interactions with CYP-metabolized drugs uses three tiers based on available evidence and theoretical risk magnitude:

• Tier 1 (Monitor): NMN/NR doses up to 500 mg/day with bupropion at standard doses (150 to 300 mg/day). Theoretical risk only; no dose adjustment needed, but disclosure to prescriber is recommended.
• Tier 2 (Caution): NMN/NR doses 500 to 1,000 mg/day with bupropion 300 to 450 mg/day. Consider checking for new CNS symptoms at each visit. No PK data available to guide further.
• Tier 3 (Discuss Alternatives or Reduce Dose): NMN/NR above 1,000 mg/day with bupropion at maximum labeled doses (450 mg/day). The combination sits in the plausible CYP2D6 inhibitory range based on in vitro Ki data. Discuss benefit-risk explicitly; document the conversation.

Evidence Quality and What Is Still Unknown

The evidence base for this specific interaction is thin. A 2023 systematic review of NMN human clinical trials identified 11 completed RCTs with a combined enrollment of fewer than 600 participants; none assessed drug-drug interactions [9]. Similarly, a 2022 review of nicotinamide riboside clinical pharmacology published in Cell Metabolism identified no formal DDI studies for NR [10]. This is a genuine gap in the literature, not a reassuring absence of signal.

What Would Establish or Rule Out the Interaction

A definitive answer would require a four-arm crossover PK study: bupropion alone, NMN 500 mg plus bupropion, NMN 2,000 mg plus bupropion, and NMN 2,000 mg alone, with serial plasma sampling for bupropion, hydroxybupropion, threohydrobupropion, and free nicotinamide. The primary endpoints would be hydroxybupropion AUC ratio and Cmax of bupropion. No such trial is registered on ClinicalTrials.gov as of July 2025.

CYP Genotype as a Modifying Variable

CYP2D6 activity varies roughly 1,000-fold across the population. Poor metabolizers (approximately 7% to 10% of European ancestry populations) [11] already have elevated bupropion-to-hydroxybupropion ratios at baseline. For a CYP2D6 poor metabolizer on bupropion, any additional CYP2D6 inhibition, even mild, could tip plasma concentrations into a higher-risk range. Ultrarapid metabolizers face the opposite concern: already-low bupropion exposure could be further complicated if NMN-derived nicotinamide shifts the metabolite balance. Pharmacogenomic testing (e.g., GeneSight or similar platforms) is worth considering for patients on bupropion 400 to 450 mg/day who want to use high-dose NAD precursors.

Practical Clinical Guidance for Patients and Prescribers

Disclosing Supplement Use

Studies show patients frequently do not report supplement use to physicians. A 2020 JAMA Internal Medicine cross-sectional analysis (N=10,197) found that 57% of adults used dietary supplements, but fewer than one-third disclosed supplement use to their medical provider [12]. For patients on bupropion, that silence is genuinely risky. Before starting NMN or NR at any dose, list it explicitly in the medication reconciliation conversation.

Dose Selection Guidance

For patients who want to take both NMN/NR and bupropion, keeping NMN/NR at 250 to 500 mg/day keeps plasma nicotinamide concentrations well below in vitro CYP2D6 inhibitory concentrations. A 2022 pharmacokinetic study (N=14) found that 300 mg NR raised plasma NR and nicotinamide modestly, with peak nicotinamide concentrations in the range of 5 to 15 micromolar [13]. At that concentration, CYP2D6 inhibition is unlikely based on the Ki data cited above [4].

Symptom Monitoring

Patients combining bupropion and NMN/NR should report any new or worsening seizure activity, unusual tremors, heightened agitation, worsening insomnia, or new headaches. These symptoms could reflect altered bupropion/hydroxybupropion ratios, though they are also common side effects of bupropion alone. A prescriber who is aware of the NMN/NR use is better positioned to evaluate cause. Bupropion trough plasma levels are available through commercial labs and may assist clinical decision-making if symptoms arise [3].

Timing and Formulation Notes

No evidence supports a specific time-separation strategy between NMN/NR and bupropion to reduce risk, because the interaction mechanism is systemic (plasma nicotinamide), not based on absorption site competition. Staggering doses by several hours does not meaningfully reduce peak plasma nicotinamide from an oral supplement. Formulation (sublingual vs. Oral capsule NMN) may affect Cmax, with sublingual routes potentially producing higher early plasma concentrations, but no comparative PK data exists for sublingual NMN in the context of CYP2D6 inhibition.

Summary of Interaction Risk by Patient Profile

| Patient Profile | Estimated Risk Level | Recommended Action | |---|---|---| | Bupropion 150 mg/day, NMN/NR 250-500 mg/day | Low (theoretical only) | Disclose to prescriber; no dose change needed | | Bupropion 300 mg/day, NMN/NR 250-500 mg/day | Low to moderate | Prescriber disclosure; monitor for CNS side effects | | Bupropion 300-450 mg/day, NMN/NR 1,000+ mg/day | Moderate (theoretical CYP2D6 range) | Discuss with prescriber; consider reducing NMN/NR dose | | CYP2D6 poor metabolizer, any bupropion dose, NMN/NR 1,000+ mg/day | Moderate to high | Pharmacogenomic-informed dosing; close monitoring | | Bupropion 450 mg/day, history of seizures, NMN/NR 2,000+ mg/day | High (theoretical) | Avoid combination or use lowest NMN/NR dose under supervision |